How compounders plan to continue making GLP-1s

Drug compounders and telemedicine companies may be ready to defy a Food and Drug Administration ban on copycat GLP-1 weight-loss drugs that takes effect on Thursday, arguing the law still allows customized versions tailored to patients' needs.
Why it matters: It would be the latest chapter in a battle with brand-name GLP-1 giants Novo Nordisk and Eli Lilly as millions try to get their hands on versions of the blockbuster drugs.
Driving the news: Noom, a digital health company that prescribes compound semaglutide, the active ingredient in some of Novo's GLP-1s, said it will continue to offer compounded versions of the drug beyond the May 22 enforcement deadline.
"The compounding law is clear," said CEO Geoff Cook. "There must be an individual patient benefit to the personalization. And so Noom works with [compounding] pharmacies to provide personalized medication when it's clinically indicated."
When prescribing a compounded GLP-1, Noom has been following a "low and slow" approach to titrating up dosages in patients in a way that is not available in commercial versions of GLP-1s.
Noom said it also prescribes brand name versions of GLP-1 products in a partnership announced earlier this year with Lilly Direct, as well as prescribing non-GLP-1 alternatives.
"I think we are looking to be on very firm ground on when it's clinically indicated," Cook said.
Yes, but: Pharma companies will likely challenge that interpretation.
"Compounders should have already transitioned patients to approved medicine, and anyone continuing to sell mass compounded tirzepatide, including by referring to it as 'personalized,' 'tailored' or something similar, is breaking the law and putting patients at risk," Eli Lilly said in a statement to Axios.
Catch up quick: The FDA allowed compounders to make cheaper copies of the drugs while they were in shortage.
When the agency declared Novo and Lilly's drugs were in sufficient supply earlier this year, compounders were put on notice that most versions of GLP-1s copies would not longer be allowed.
The compounding labs filed a challenge to put tirzepatide, the active ingredient in Lilly's GLP-1s, back in shortage. Earlier this month, a judge ruled against them.
The FDA also allows compounding for prescriptions specific to particular patients.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

USA Today

15 minutes ago

• USA Today

Novo Nordisk halts Wegovy deal with Hims & Hers, triggering 31% stock drop

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health HIMS.N, pushing Hims shares down 31% in morning trading. The two companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through a bundled offering on the telehealth company's platform. The end of the collaboration means Hims will no longer be able to sell branded Wegovy drugs. Novo said that Hims & Hers' decision to continue supplying doses of compounded semaglutide - the active ingredient in Wegovy - was not in accordance with the law because the drug was no longer in shortage. The U.S. Food and Drug Administration had allowed compounded versions made by pharmacies during the drug's shortage. In case you missed it: Wegovy weight-loss drug discounted to $199 until July, but there's a catch Earlier this month, Hims said that it would continue selling "personalized" doses of semaglutide, starting at around $165 a month. Hims has said personalized doses are allowed for patients who need different doses for clinical reasons such as limiting side effects. Hims & Hers shares were trading at $44.55 on Monday. Hims also sells liraglutide, a generic version of another older Novo diabetes drug that causes weight loss, as well as Eli Lilly's LLY.N rival Zepbound. Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it. Hims & Hers was not immediately available for a comment. A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list. "Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said. Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims & Hers fell 22% to $50.02 in U.S. premarket hours. Reporting by Louise Breusch Rasmussen, Bhanvi Satija and Amina Niasse; Editing by Terje Solsvik, Catherine Evans and Aidan Lewis

The Hill

29 minutes ago

• The Hill

Trump's 50 percent aluminum, steel tariffs will create new American manufacturing jobs

At the G-7 meetings in Canada last week, President Trump reaffirmed his commitment to put American manufacturing workers first. Our president previously told thousands of steel workers in Pennsylvania that 'we are going to bring it from 25 percent to 50 percent' the tariffs 'to further secure' domestic steel and aluminum manufacturing. Trump keeps telling Prime Minister Mark Carney that 'we really don't want Canadian steel and we don't want Canadian aluminum because we want to be able to do it ourselves.' As Trump's chief of staff during his first term, I travelled with him across our great country and saw firsthand his commitment to rebuild manufacturing communities that had been hollowed out by foreign countries engaging in unfair trade practices. Upon reassuming office, Trump moved swiftly to sign new Section 232 national security proclamations and most recently increased the tariffs from 25 percent to 50 percent to stop American aluminum and steel workers getting ripped off. While the targeted tariffs were met with hysteria by the left-wing media and Canadian backed special interest groups, American manufacturing workers reacted with joy. In my home state of North Carolina, we have seen firsthand what happens when foreign producers take aim at American manufacturing. Aluminum, steel, furniture and textile manufacturing have been devastated by foreign government subsidized cheap products imported into the United States. Families suffer and jobs are lost and most of those jobs, sadly, will never return. Now globalist elites that are heavily funded by non-U.S. interest groups are pushing for Canada to get an exemption or an alternative agreement to avoid the Section 232 aluminum tariff. Canada's aluminum industry must not be rewarded at the expense of thousands of American aluminum jobs. The Organization for Economic Development and Co-operation has reported on Canada's subsidization of its electricity industry for the benefit of its aluminum producers. The simple reality is that the Canadian government provides significant subsidies to its aluminum industry, in the form of cheap electricity. Canada handed out over $850 million in subsidies to its aluminum industry. Here in the United States, domestic producers purchase electricity in accordance with free market principles. During my time at the White House, Canadian aluminum imports surged by 47 percent by mid-2020 after Canada was granted a tariff exemption a year prior. The Canadian aluminum surge devastated American manufacturing families and led to the closure of three U.S. aluminum smelter. Seven hundred American aluminum workers lost their jobs in Washington state, 400 aluminum workers lost their jobs in Missouri and 600 aluminum workers lost their jobs in Kentucky. At the time, President Biden could have used the mechanisms in the United States-Mexico-Canada Agreement we negotiated to reimpose relief and stop the bleeding after the first smelter closed. Instead, Biden under pressure from the same globalist groups, allowed the Canadian government and industry to keep their exemption and siphon off American jobs. We cannot allow history to repeat itself. Now in 2025, the globalist aluminum associations and their foreign proxies are once again saying there must be zero tariffs on Canadian aluminum and peddling the same sky-is-falling rhetoric they used previously about Trumps' targeted aluminum and steel tariffs. The sad reality is that these globalist special interest groups are more interested in lining the pockets of their members with foreign plants rather than putting American manufacturing workers first. In 2000, there were 23 U.S. aluminum smelters and 10 in Canada. Today, there are still 10 aluminum smelters in Canada thanks to the Canadian government's subsidies and only four aluminum plants remaining in the United States, a staggering 82 percent reduction in U.S. production capacity. Any exemption or special deal for Canadian aluminum will likely destroy the rest of our domestic industry and result in thousands of American jobs lost. Our president is right, the U.S. is 'done subsidizing Canada' and no exemptions for countries that have a track record of not playing by the rules. The president is not fighting for foreign countries like Canada and Mexico that rip us off on trade, he is fighting for you, your family's future and millions of American manufacturing workers. With over $14 billion in new U.S. investment announced, Trump's 50 percent aluminum and steel tariffs address the root cause of the cheating and unleash a new Golden Age for our country. Now is the time to cast aside the loud voices of these radical globalist special interest groups that seek to undermine Trump's trade agenda. Mark Meadows served as the 29th White House chief of staff and as a member of Congress for North Carolina's 11th District from 2013 to 2020.

Axios

2 hours ago

• Axios

Jennifer Aniston's favorite workout is coming to Charlotte

Pvolve, a women's fitness brand backed by Jennifer Aniston, is opening a studio in Dilworth this fall. Why it matters: The Charlotte location, which will be locally owned and operated, marks the brand's expansion into North Carolina. How it works: Pvolve is built around functional fitness and women's wellness, explains franchise owner Mariana Lim. Classes are designed to build strength, mobility and longevity for women in all stages of life, from postpartum to menopause. Functional fitness generally refers to exercise that advances physiological function and involves daily movements like squatting, bending, pushing and lunging. The Pvolve method blends elements of yoga, Pilates and strength training into a 50-minute, low-impact workout. A few of the most popular classes include: Strength & Sculpt: Pvolve's signature class to sculpt and tone the full body through low-impact exercises. Progressive Weight Training: A mix of weight training with dynamic functional movements. Ideal for women over 40 or those looking to build strength. Mat Definition: A Pilates-inspired mat class with a focus on the core. There are also more specialized offerings, like a pelvic floor class and a series for people taking GLP-1 medications, aimed at preserving muscle mass while losing weight. What to expect: The Charlotte studio will join the retail lineup at The Seventeen Hundred, a new multi-family development under construction along East Boulevard in Dilworth. Lim is targeting an early November opening, she tells Axios. Limited founding memberships will launch in August. A standard unlimited membership will be $259/month. HSA funds can be put towards classes, according to Lim. The Charlotte studio will have 23 mats, a locker room, beauty bar, secure lockers and a private room for personal training sessions, says Lim. The intrigue: A major component of Pvolve's business model is its hybrid membership, offering classes both in-studio and through an online streaming platform. Pvolve sells equipment bundles for at-home workouts, like its $664 "Total Transformation Bundle," a 13-piece set of "toning tools," like weights, bands and the "P. Ball" (a mix of a Pilates ball and resistance band). Context: The company began in New York City's Chinatown in 2017 by entrepreneur Rachel Katzman, who was seeking a low-impact alternative to traditional functional fitness. Jennifer Aniston discovered the brand in 2021 through its streaming platform. A fan of the results, she joined the board in 2023, and according to a blog post, now helps shape product development, programming, and marketing to build Pvolve's brand awareness. Pvolve is actively franchising with over 50 studios across the country. The closest operating studio is in Columbia, South Carolina. What they're saying: Pvolve's approach to fitness will bring something new to Charlotte, especially for women, says Lim. Originally from Brazil, Lim has lived in Charlotte for 15 years and says she's taken nearly every class in town. What's next: Lim says she's planning to host several pop-up classes later this summer. Stop by: Pvolve Charlotte will open at 1701 East Blvd.